Congratulations to our client NEUVOGEN, Inc.for appointing Roger Sawhney as Chief Business Officer.
NEUVOGEN, Inc. is a San-Diego based biotechnology company focused on developing whole cell cancer vaccine therapies. NEUVOGEN believes its cancer vaccines have the broadest combination of tumor associated antigens and tumor specific antigens delivered in a cancer vaccine. As a result, these next-generation cancer vaccines can directly target a greater percentage of cancer cells in a solid tumor than any previous cancer vaccine. NEUVOGEN’s goal is to develop therapeutic cancer vaccines that activate the body’s immune system to treat primary tumors, micrometastases, and metastases. In turn, these agents can delay and prevent relapses in early and late-stage disease and meaningfully extend the lives of patients with minimal side effects.
C1 Team: Christos Richards & James Reynolds